your initial deposit *subject to change and depends on individual circumstances.
Diamedica is a biotechnology company focused on the development of treatments for Type 2 diabetes. The Company's lead candidate, DM-71, is in Phase II clinical studies to determine its effectiveness as compared to a placebo treatment.
Recent Sector News
THE BIG PICTURE - Oxford Pharmascience at inflection point as it moves towards commercialising pipeline
Oxford Pharmascience is now at an 'inflection point' as it moves towards commercialising its drug pipeline.
Marcelo Bravo, founder and previous chief technological officer of drug reformulation specialist Oxford Pharmascience is now at the helm, the firm told investors, as it posted 2013 results, which showed strong sales
The speciality pharma and pharmaceutical services group Clinigen revealed itself to be in rude financial health, posting a 20% rise in underlying first half earnings.
Euronext listed Nanobiotix has been able to bring forward the launch of its lead product in a drive by the company to transform radiotherapy, using Nanotechnology. Proactive's Jeremy Naylor interviewed Philippe Mauberna, chief financial officer, who revealed the huge potential of the company's NanoXray technology.
America’s love affair with biotechnology is well charted. The pull is clear, but there are indications that European investors are starting to wake up to the potential of the sector and invest in biotechs.
Les actions Nanobiotix explosent après la possible mise sur le marché anticipée de son produit phare
Les actions de la société Nanobiotix (EPA:NANO) bondissaient encore mercredi alors que le groupe, qui compte révolutionner la radiothérapie en utilisant la nanotechnologie, révélait que son produit phare va être mis sur le marché plus tôt que prévu.
Investors interested in Diamedica recently viewed
- Stirling Products (ASX: STI) Your wellbeing is our priority
- ReNeuron (AIM: RENE) Leading stem cell company targeting areas of significant unmet medical need
- Circadian Technologies (ASX: CIR) .
- Acuvax soon to be renamed Biolife Science Limited (ASX: ACU) .
- Plethora Solutions (AIM: PLE) products for the treatment and management of urological disorders